A growing percentage of CLL patients will receive both a BTK inhibitor (BTKi) and BCL-2 inhibitor, considered “double exposed”, with the expanding use of both classes of drugs: as monotherapy, in combination with anti-CD20 monoclonal antibodies, concurrently, and sequentially. Here, BTK is linked to B-cell chronic lymphocytic leukemia.